Navigation Links
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Date:4/15/2008

Novel Nucleoside-Sparing Regimen Designed to Avoid Risk of Toxicity

Associated with Nucleoside Class of HIV Drugs

KENILWORTH, N.J., April 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has initiated a Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. Vicriviroc is a next-generation HIV entry inhibitor designed to prevent the virus from infecting CD4 cells by blocking its predominant entry route, the CCR5 co-receptor. Approximately 80-90 percent of treatment-naive patients have virus that uses the CCR5 co-receptor.(1) Vicriviroc also is being studied in two large Phase III clinical studies in treatment-experienced HIV patients, which are ongoing and currently enrolling patients.

The study in treatment-naive patients evaluates the virologic benefit of vicriviroc, administered once-daily as a single 30 mg tablet, in combination with ritonavir-boosted atazanavir,(2) compared to a control group receiving Truvada (emtricitabine and tenofovir disoproxil fumarate)(3) plus ritonavir- boosted atazanavir, which is a currently recommended option for first-line therapy. Atazanavir is a product in the protease inhibitor (PI) class of HIV medications. Truvada is a combination product in the nucleoside reverse transcriptase inhibitor (NRTI) class.

"A nucleoside-sparing vicriviroc regimen for initial treatment may have the added strategic benefit of preserving most products used to create a highly active antiretroviral therapy "cocktail" for later use in patients, while also avoiding the risk of toxicity known to be associated with the nucleoside
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Schering-Plough Reports Top-Line Results of the IDEAL Study
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
7. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 The saturated European ... from the rising incidence of preterm births. This trend ... care unit (NICU) devices but also skilled and trained ... from Frost & Sullivan, Analysis of the Western European ... revenues of $151.5 million in 2014 and estimates this ...
(Date:4/21/2015)... April 21, 2015 EUSA Pharma ... reach, today announced the appointment of Lee Morley ... as a Non-Executive Director.  Bryan Morton, who established EUSA ... Chairman.   Lee Morley joins ... President, Head of Commercial for Europe ...
(Date:4/21/2015)... April 21, 2015  Legal-Bay LLC, The Lawsuit ... Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for ... According to PBR, Boehringer submitted a supplemental new ... that Pradaxa will be approved for the prophylaxis ... (PE) for patients who have undergone a primary ...
Breaking Medicine Technology:Rising Numbers of Preterm Births Stoke Demand for Infant Care Solutions in Europe 2Rising Numbers of Preterm Births Stoke Demand for Infant Care Solutions in Europe 3EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 2EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 3Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 2Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 3
... SARcode Corporation presented data today for their lead investigational ... trial, subjects receiving SAR 1118 demonstrated a reduction in ... as compared to placebo. These data were part of ... Vision and Ophthalmology (ARVO) Annual Meeting held in Fort ...
... 3, 2011 At the Board of Directors meeting held ... per share. The dividend is payable on June 15, 2011 ... About Sigma-Aldrich: Sigma-Aldrich is a leading ... to Improve the Quality of Life. Its chemical and biochemical ...
Cached Medicine Technology:SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 2SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 3
(Date:4/21/2015)... United Benefit Advisors (UBA), the nation’s ... to welcome Power Kunkle Benefits Consulting as its ... Jeff Power have been committed to providing the ... more than 450 clients. For Power Kunkle Benefits ... stewardship, ethical consulting, and measurable results. , ...
(Date:4/21/2015)... 2015 Atlantic Information Services, Inc. ... Medicare-Medicaid Dual Eligibles Database, a brand-new, continually updated ... to the more than 9 million Medicare-Medicaid dual ... than $300 billion in annual health care spending. ... team that also creates the industry-leading AIS’s Directory ...
(Date:4/21/2015)... Nashville, Tenn. – Radsource, a leader ... Archiving and Communication Systems (PACS), has expanded its ... the first quarter of 2015. , Kentucky Breast ... and Lowcountry Orthopaedics & Sports Medicine (Charleston, SC) ... services. Mt. San Rafael Hospital (Trinidad, CO) will ...
(Date:4/21/2015)... eSight is the only technology in the world that ... Tuesday, May 5th, Low Vision Specialists of Maryland and ... an unveiling and demonstration of the technology at 8:30 a.m ... will be the first ophthalmic practice in Maryland to offer ... will be available on the day of the unveiling. , ...
(Date:4/21/2015)... 2015 With a growing number of ... Worldwide indicates that international political instability and terrorism top ... survey by Clements, a global insurance provider with 68 ... their country of citizenship, also found strong concern but ... health care insurance overseas . , Asked to choose ...
Breaking Medicine News(10 mins):Health News:Power Kunkle Benefits Consulting Is the Latest Partner Firm To Join United Benefit Advisors 2Health News:New AIS Database Tracks All Programs, Plans Serving the Dual-Eligible Community 2Health News:Radsource Adds 4 ProtonPACS Clients in 1st Quarter 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 3Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 2Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 3
... types of blood pressures -- systolic pressure is created by ... the vessels and diastolic pressure is when the heart is ... is 120/80. The first number in a blood pressure reading ... is the diastolic pressure. ,A recent study shows ...
... According to a recent study conducted researchers suggest that ... from // having their tonsils and adenoids out. ... States. Most of the time, it is performed to ... however, doctors have also used the surgery to treat ...
... of hospitalization among people 65 or older but is ... heart damage or complications and the costs of care. ... test for high levels of the peptide in patients ... have congestive heart failure, in which the heart stops ...
... cancer in the United States. According to a recent study ... In addition, soy protein may help minimize the number and ... diets to female mice and followed their progress for one ... specific ingredients. Diet one contained milk protein, and diet two ...
... Previous studies show conflicting results over whether hormone replacement ... A recent study examines the pros and cons of ... combined HRT therapy for five years. All the women ... had menopausal symptoms, while others did not.Results show women ...
... with 32,800 middle-aged women has shown that there may be ... no risk factors whose blood has high amounts of iron.// ... in 1989-90 from women with no history of diabetes, cardiovascular ... had shown an average iron concentration of 109 nanograms/milliliter manifested ...
Cached Medicine News:Health News:Study On Self Measurement Of Blood Pressure 2Health News:‘Protein’ Produced By Overstressed Heart Muscle a Strong Indicator Of Heart Disea 2
9 mm slightly curved blade. Hexagonal handle....
9 mm blade....
4 mm disposable bevel blade. Malleable shafts. Flat spot on handle designed to guide knife in perforation....
Storz Ear Knife Handle....
Medicine Products: